Monoclonal Antibodies Show Promise in Fight Against COVID-19

December 7, 2021

For high-risk patients newly diagnosed with COVID-19, the U.S. Department of Health and Human Services (HHS) reports that physicians have an available tool that may prevent serious illness and death. Monoclonal antibodies, while reportedly not being used as widely as they could be, have been shown to be effective when administered early in the disease progression. The antibodies can reduce COVID-19 symptoms and hospitalizations. HHS offers information on how to obtain therapeutic monoclonal antibodies.
While this treatment may reduce the risk of severe illness and hospitalization for your patients, the best protection continues to be for everyone over the age of five to become fully vaccinated and to receive booster shots when eligible, according to the Centers for Disease Control and Prevention.
On the horizon for the New Year: Merck and Pfizer are developing oral antiviral regimens in pill form that are intended for patients who test positive for COVID-19. In clinical trials, Pfizer’s treatment reduced the risk of hospitalization or death by 89% and Merck’s regimen by about 50%. These pills are expected to be approved by the Food and Drug Administration early in 2022.
ISMIE offers a wide array of COVID-19 resources to help policyholders navigate the various aspects of the pandemic, including vaccine hesitancy, telemedicine, burnout and more.
For more information, contact the Risk Management team.
Share this article:

Cookie Consent

Cookies are required for some functionality on our site. View our privacy policy for more information.